Abstract
Objective: To evaluate the 24-week effects on glucose tolerance of switching from a protease inhibitor (PI)-based to an unboosted atazanavir-including regimen in highly pretreated HIV-1 infected subjects with metabolic alterations. Design: Prospective, open-label, single-center, 24-week pilot study. Methods: Twenty-one subjects underwent an oral glucose tolerance test (OGTT) at baseline (BL) and after 24 weeks of unboosted atazanavir. Insulin sensitivity and β-cell responsiveness were evaluated on the basis of static and dynamic data; fasting glucose, insulin, C-peptide, triglycerides (TG), total cholesterol (TC), high-density lipoprotein-cholesterol (HDI-c), low-density lipoprotein-cholesterol (IDL-c), TC/HDL ratio, CD4+ cell count and HIV-1 RNA were measured. Results: After 24 weeks of unboosted atazanavir, the 120-min glucose level was significantly lower than the one measured at BL (P=0.021); there were no statistically significant differences in the insulin concentration proffie. The SIoral, an OGTT-based index of insulin sensitivity, was significantly higher at week 24 (P = 0.017); the indices of first- and second-phase β-cell responsiveness did not significantly change. There was no significant difference between BL and 24-week fasting glucose, insulin or C-peptide levels and consequently no change in fasting homeostasis model assessment indices of insulin sensitivity and β-cell function. There were significant improvements in TG (P = 0.009), TC (P = 0.0001), LDL-c (P = 0.019) and TC/HDL-c ratio (P = 0.001), and a similar trend in HDT-c levels (P = 0.069). No significant changes in the immunological and virological parameters were detected. Conclusions: Our results show that switching from a PI-based to an unboosted atazanavir-including regimen leads to a significant improvement in glucose tolerance in highly pretreated HIV-1 infected subjects with metabolic alterations.
| Original language | English |
|---|---|
| Pages (from-to) | 503-509 |
| Number of pages | 7 |
| Journal | European Journal of Endocrinology |
| Volume | 156 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 2007 |
Fingerprint
ASJC Scopus subject areas
- Endocrinology
Cite this
Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects. / Gulffanti, Monica; Caumo, Andrea; Galli, Laura; Bigoloni, Alba; Galli, Andrea; Dagba, Geneviéve; Danise, Anna; Luzi, Livio; Lazzarin, Adriano; Castagna, Antonella.
In: European Journal of Endocrinology, Vol. 156, No. 4, 04.2007, p. 503-509.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects
AU - Gulffanti, Monica
AU - Caumo, Andrea
AU - Galli, Laura
AU - Bigoloni, Alba
AU - Galli, Andrea
AU - Dagba, Geneviéve
AU - Danise, Anna
AU - Luzi, Livio
AU - Lazzarin, Adriano
AU - Castagna, Antonella
PY - 2007/4
Y1 - 2007/4
N2 - Objective: To evaluate the 24-week effects on glucose tolerance of switching from a protease inhibitor (PI)-based to an unboosted atazanavir-including regimen in highly pretreated HIV-1 infected subjects with metabolic alterations. Design: Prospective, open-label, single-center, 24-week pilot study. Methods: Twenty-one subjects underwent an oral glucose tolerance test (OGTT) at baseline (BL) and after 24 weeks of unboosted atazanavir. Insulin sensitivity and β-cell responsiveness were evaluated on the basis of static and dynamic data; fasting glucose, insulin, C-peptide, triglycerides (TG), total cholesterol (TC), high-density lipoprotein-cholesterol (HDI-c), low-density lipoprotein-cholesterol (IDL-c), TC/HDL ratio, CD4+ cell count and HIV-1 RNA were measured. Results: After 24 weeks of unboosted atazanavir, the 120-min glucose level was significantly lower than the one measured at BL (P=0.021); there were no statistically significant differences in the insulin concentration proffie. The SIoral, an OGTT-based index of insulin sensitivity, was significantly higher at week 24 (P = 0.017); the indices of first- and second-phase β-cell responsiveness did not significantly change. There was no significant difference between BL and 24-week fasting glucose, insulin or C-peptide levels and consequently no change in fasting homeostasis model assessment indices of insulin sensitivity and β-cell function. There were significant improvements in TG (P = 0.009), TC (P = 0.0001), LDL-c (P = 0.019) and TC/HDL-c ratio (P = 0.001), and a similar trend in HDT-c levels (P = 0.069). No significant changes in the immunological and virological parameters were detected. Conclusions: Our results show that switching from a PI-based to an unboosted atazanavir-including regimen leads to a significant improvement in glucose tolerance in highly pretreated HIV-1 infected subjects with metabolic alterations.
AB - Objective: To evaluate the 24-week effects on glucose tolerance of switching from a protease inhibitor (PI)-based to an unboosted atazanavir-including regimen in highly pretreated HIV-1 infected subjects with metabolic alterations. Design: Prospective, open-label, single-center, 24-week pilot study. Methods: Twenty-one subjects underwent an oral glucose tolerance test (OGTT) at baseline (BL) and after 24 weeks of unboosted atazanavir. Insulin sensitivity and β-cell responsiveness were evaluated on the basis of static and dynamic data; fasting glucose, insulin, C-peptide, triglycerides (TG), total cholesterol (TC), high-density lipoprotein-cholesterol (HDI-c), low-density lipoprotein-cholesterol (IDL-c), TC/HDL ratio, CD4+ cell count and HIV-1 RNA were measured. Results: After 24 weeks of unboosted atazanavir, the 120-min glucose level was significantly lower than the one measured at BL (P=0.021); there were no statistically significant differences in the insulin concentration proffie. The SIoral, an OGTT-based index of insulin sensitivity, was significantly higher at week 24 (P = 0.017); the indices of first- and second-phase β-cell responsiveness did not significantly change. There was no significant difference between BL and 24-week fasting glucose, insulin or C-peptide levels and consequently no change in fasting homeostasis model assessment indices of insulin sensitivity and β-cell function. There were significant improvements in TG (P = 0.009), TC (P = 0.0001), LDL-c (P = 0.019) and TC/HDL-c ratio (P = 0.001), and a similar trend in HDT-c levels (P = 0.069). No significant changes in the immunological and virological parameters were detected. Conclusions: Our results show that switching from a PI-based to an unboosted atazanavir-including regimen leads to a significant improvement in glucose tolerance in highly pretreated HIV-1 infected subjects with metabolic alterations.
UR - http://www.scopus.com/inward/record.url?scp=34247629373&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247629373&partnerID=8YFLogxK
U2 - 10.1530/EJE-06-0648
DO - 10.1530/EJE-06-0648
M3 - Article
VL - 156
SP - 503
EP - 509
JO - European Journal of Endocrinology
JF - European Journal of Endocrinology
SN - 0804-4643
IS - 4
ER -